Julie Schneider to Biomarkers
This is a "connection" page, showing publications Julie Schneider has written about Biomarkers.
Connection Strength
0.351
-
Outcome markers for clinical trials in cerebral amyloid angiopathy. Lancet Neurol. 2014 Apr; 13(4):419-28.
Score: 0.091
-
Elevated neuroinflammation, autoimmunity, and altered IgG glycosylation profile in the cerebral spinal fluid of severe COVID-19 patients. Brain Behav Immun. 2025 Aug; 128:289-302.
Score: 0.049
-
Antiphospholipid Antibodies: Cognitive and Motor Decline, Neuroimaging and Neuropathology. Neuroepidemiology. 2019; 53(1-2):100-107.
Score: 0.033
-
Seasonal plasticity of cognition and related biological measures in adults with and without Alzheimer disease: Analysis of multiple cohorts. PLoS Med. 2018 09; 15(9):e1002647.
Score: 0.031
-
The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. Alzheimers Dement. 2018 04; 14(4):563-575.
Score: 0.030
-
Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer's disease pathology. Alzheimers Dement. 2016 09; 12(9):942-951.
Score: 0.026
-
First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementia. J Transl Med. 2016 Feb 13; 14:50.
Score: 0.026
-
Cerebrovascular and microglial states are not altered by functional neuroinflammatory gene variant. J Cereb Blood Flow Metab. 2016 Apr; 36(4):819-30.
Score: 0.026
-
Antiphospholipid antibodies, brain infarcts, and cognitive and motor decline in aging (ABICMA): design of a community-based, longitudinal, clinical-pathological study. Neuroepidemiology. 2013; 40(2):73-84.
Score: 0.021
-
Evidence of angiogenic vessels in Alzheimer's disease. J Neural Transm (Vienna). 2009 May; 116(5):587-97.
Score: 0.016